Trends in annualized relapse rates in relapsing-remitting multiple sclerosis and consequences for clinical trial design

Multiple Sclerosis Journal

Volumn 17, Issue 10, 2011, Pages 1211-1217

  Nicholas, Richard ^a   Straube, Sebastian ^b   Schmidli, Heinz ^c   Schneider, Simon ^b   Friede, Tim ^b  

^a IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

adaptive design; annualized relapse rate; blinded sample size review; computer simulations; relapsing remitting multiple sclerosis; systematic review

Indexed keywords

ARTICLE; COCHRANE LIBRARY; COMPUTER SIMULATION; HUMAN; MEDLINE; MULTIPLE SCLEROSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; SYSTEMATIC REVIEW;

EID: 80053599717     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458511406309     Document Type: Article

References (24)

1. Inusah S, Sormani MP, Cofield SS, Aban IB, Musani SK, Srinivasasainagendra V, et al. Assessing changes in relapse rates in multiple sclerosis. Mult Scler. 2010 ; 16: 1414-1421
2. Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010 ; 362: 387-401
3. Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg Sørensen P, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010 ; 362: 416-26
4. Guidance for industry-Adaptive design clinical trials for drugs and biologics. Draft guidance, 2010. Food and Drug Administration ; 2010 :
5. Cook RJ, Bergeron PJ, Boher JM, Lie Y. Two-stage design of clinical trials involving recurrent events. Stat Med. 2009 ; 28: 2617-2638
6. Friede T, Schmidli H. Blinded sample size reestimation with count data: methods and applications in multiple sclerosis. Stat Med. 2010 ; 29: 1145-1156
7. Friede T, Schmidli H. Blinded sample size reestimation with negative binomial counts in superiority and non-inferiority trials. Methods Inf Med. 2010 ; 49: 618-624
8. Sormani MP, Laura Bonzano L, Roccatagliata L, Cutter GR, Mancardi GL, Bruzzi P. Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach. Ann Neurol. 2009 ; 65: 268-275
9. Wang YC, Meyerson L, Tang YQ, Qian N. Statistical methods for the analysis of relapse data in MS clinical trials. J Neurol Sci. 2009 ; 285: 206-211
10. Furman E. On the convolution of the negative binomial random variables. Stat Probab Lett. 2007 ; 77: 169-172 (Pubitemid 44742884)
11. Ng HKT, Tang M-L. Testing the equality of two Poisson means using the rate ratio. Stat Med. 2005 ; 24: 955-965 (Pubitemid 40403177)
12. Friede T, Kieser M. Sample size recalculation in internal pilot study designs: a review. Biom J. 2006 ; 48: 537-555 (Pubitemid 44367892)
13. Benda N, Branson M, Maurer W, Friede T. Aspects of modernizing drug development using scenario planning and evaluation. Drug Inf J. 2010 ; 44: 299-315
14. Chataway J, Nicholas R, Todd S, Parsons N, Todd S, Miller D, et al. A novel adaptive design strategy increases the efficiency of clinical trials in secondary progressive multiple sclerosis. Mult Scler. 2011 ; 17: 81-88
15. Friede T, Nicholas R, Stallard N, Todd S, Parsons N, Valdés- Márquez E, et al. Refinement of the Clinical Scenario Evaluation framework for assessment of competing development strategies with an application to multiple sclerosis. Drug Inf J. 2010 ; 44: 713-718
16. Kappos L, Gold R, Miller DH, MacManus DG, Havrdova E, Limmroth V, et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet. 2008 ; 372: 1463-1472
17. Ebers GC, Traboulsee A, Li D, Langdon D, Reder AT, Goodin DS, et al. Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial. J Neurol Neurosurg Psychiatry. 2010 ; 81: 907-912
18. Guideline on clinical investigation of medicinal products for the treatment of multiple sclerosis. Doc. Ref. EMEA/CHMP/EWP/561/98 Rev 1. London: CHMP ; 2005 :
19. Scalfari A, Neuhaus A, Degenhardt A, Rice GP, Muraro PA, Daumer M, et al. The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability. Brain. 2010 ; 133: 1914-1929
20. ICH Harmonised Tripartite Guideline E9: Statistical principles for clinical trials. Stat Med. 1999 ; 18: 1905-1942
21. European Medicines Agency (EMA). Reflection paper on methodological issues in confirmatory clinical trials planned with an adaptive design. CHMP/EWP/2459/02, 2007. Available from: http://www.emea.europa.eu/pdfs/human/ ewp/245902enadopted.pdf (accessed 12 February 2011).
22. Jennison C, Turnbull BW Group sequential methods with applications to clinical trials. Chapman & Hall/CRC ; 2000 :
23. Gaydos B, Anderson K, Berry DA, Burnham N, Chuang-Stein C, Dudinak J, et al. Good practices for adaptive clinical trials in pharmaceutical product development. Drug Inf J. 2009 ; 43: 539-556
24. Polman CH, Reingold SC, Barkhof F, Calabresi PA, Clanet M, Cohen JA, et al. Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment. Neurology. 2008 ; 70: 1134-1140 (Pubitemid 351464771)